Literature DB >> 29548671

A Neutralizing Antibody Recognizing Primarily N-Linked Glycan Targets the Silent Face of the HIV Envelope.

Tongqing Zhou1, Anqi Zheng1, Ulrich Baxa2, Gwo-Yu Chuang1, Ivelin S Georgiev3, Rui Kong1, Sijy O'Dell1, Syed Shahzad-Ul-Hussan4, Chen-Hsiang Shen1, Yaroslav Tsybovsky2, Robert T Bailer1, Syna K Gift5, Mark K Louder1, Krisha McKee1, Reda Rawi1, Catherine H Stevenson1, Guillaume B E Stewart-Jones1, Justin D Taft1, Eric Waltari6, Yongping Yang1, Baoshan Zhang1, Sachin S Shivatare7, Vidya S Shivatare7, Chang-Chun D Lee7, Chung-Yi Wu7, James C Mullikin8, Carole A Bewley9, Dennis R Burton10, Victoria R Polonis11, Lawrence Shapiro12, Chi-Huey Wong13, John R Mascola14, Peter D Kwong15, Xueling Wu16.   

Abstract

Virtually the entire surface of the HIV-1-envelope trimer is recognized by neutralizing antibodies, except for a highly glycosylated region at the center of the "silent face" on the gp120 subunit. From an HIV-1-infected donor, #74, we identified antibody VRC-PG05, which neutralized 27% of HIV-1 strains. The crystal structure of the antigen-binding fragment of VRC-PG05 in complex with gp120 revealed an epitope comprised primarily of N-linked glycans from N262, N295, and N448 at the silent face center. Somatic hypermutation occurred preferentially at antibody residues that interacted with these glycans, suggesting somatic development of glycan recognition. Resistance to VRC-PG05 in donor #74 involved shifting of glycan-N448 to N446 or mutation of glycan-proximal residue E293. HIV-1 neutralization can thus be achieved at the silent face center by glycan-recognizing antibody; along with other known epitopes, the VRC-PG05 epitope completes coverage by neutralizing antibody of all major exposed regions of the prefusion closed trimer.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HIV silent face; HIV vaccine; broadly neutralizing antibody; crystal structure; glycan cluster; glycan recognition; glycopeptide epitope; prefusion-closed Env trimer; viral escape

Mesh:

Substances:

Year:  2018        PMID: 29548671      PMCID: PMC6421865          DOI: 10.1016/j.immuni.2018.02.013

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  35 in total

1.  Mutational fitness landscapes reveal genetic and structural improvement pathways for a vaccine-elicited HIV-1 broadly neutralizing antibody.

Authors:  Bharat Madan; Baoshan Zhang; Kai Xu; Cara W Chao; Sijy O'Dell; Jacy R Wolfe; Gwo-Yu Chuang; Ahmed S Fahad; Hui Geng; Rui Kong; Mark K Louder; Thuy Duong Nguyen; Reda Rawi; Arne Schön; Zizhang Sheng; Rajani Nimrania; Yiran Wang; Tongqing Zhou; Bob C Lin; Nicole A Doria-Rose; Lawrence Shapiro; Peter D Kwong; Brandon J DeKosky
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-09       Impact factor: 11.205

2.  The barley lectin, horcolin, binds high-mannose glycans in a multivalent fashion, enabling high-affinity, specific inhibition of cellular HIV infection.

Authors:  Nisha Grandhi Jayaprakash; Amrita Singh; Rahul Vivek; Shivender Yadav; Sanmoy Pathak; Jay Trivedi; Narayanaswamy Jayaraman; Dipankar Nandi; Debashis Mitra; Avadhesha Surolia
Journal:  J Biol Chem       Date:  2020-07-07       Impact factor: 5.157

Review 3.  Subdominance in Antibody Responses: Implications for Vaccine Development.

Authors:  Gunnar Lindahl
Journal:  Microbiol Mol Biol Rev       Date:  2020-11-25       Impact factor: 11.056

Review 4.  The antibody response in HIV-1-infected donors.

Authors:  Simone I Richardson; Penny L Moore
Journal:  Curr Opin HIV AIDS       Date:  2019-07       Impact factor: 4.283

Review 5.  Harnessing post-translational modifications for next-generation HIV immunogens.

Authors:  Joel D Allen; Rogier W Sanders; Katie J Doores; Max Crispin
Journal:  Biochem Soc Trans       Date:  2018-05-21       Impact factor: 5.407

Review 6.  The Glycoscience of Immunity.

Authors:  Julie Y Zhou; Douglas M Oswald; Kelsey D Oliva; Lori S C Kreisman; Brian A Cobb
Journal:  Trends Immunol       Date:  2018-05-11       Impact factor: 16.687

7.  Mapping Polyclonal Antibody Responses in Non-human Primates Vaccinated with HIV Env Trimer Subunit Vaccines.

Authors:  Bartek Nogal; Matteo Bianchi; Christopher A Cottrell; Robert N Kirchdoerfer; Leigh M Sewall; Hannah L Turner; Fangzhu Zhao; Devin Sok; Dennis R Burton; Lars Hangartner; Andrew B Ward
Journal:  Cell Rep       Date:  2020-03-17       Impact factor: 9.423

8.  Automated Design by Structure-Based Stabilization and Consensus Repair to Achieve Prefusion-Closed Envelope Trimers in a Wide Variety of HIV Strains.

Authors:  Reda Rawi; Lucy Rutten; Yen-Ting Lai; Adam S Olia; Sven Blokland; Jarek Juraszek; Chen-Hsiang Shen; Yaroslav Tsybovsky; Raffaello Verardi; Yongping Yang; Baoshan Zhang; Tongqing Zhou; Gwo-Yu Chuang; Peter D Kwong; Johannes P M Langedijk
Journal:  Cell Rep       Date:  2020-11-24       Impact factor: 9.423

Review 9.  Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research.

Authors:  Denise A Cobb; Nathan A Smith; Benson J Edagwa; JoEllyn M McMillan
Journal:  Expert Opin Drug Deliv       Date:  2020-07-06       Impact factor: 6.648

10.  Cross-Neutralizing CRF01_AE-Infected Plasma from Malaysia Targets CD4-Binding Site of Human Immunodeficiency Virus Type-1 Envelope Glycoprotein.

Authors:  Qi Ron Ng; Kok Keng Tee; James M Binley; Tommy Tong
Journal:  AIDS Res Hum Retroviruses       Date:  2021-06-17       Impact factor: 1.723

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.